Celldex Therapeutics provided clinical updates on barzolvolimab, including plans to initiate a second Phase III trial for Chronic Inducible Urticaria and release Phase II data for EoE.
1 report, 0 independent
Updated Jun 24
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Celldex Therapeutics provided clinical updates on barzolvolimab, including plans to initiate a second Phase III trial for Chronic Inducible Urticaria and release Phase II data for EoE.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Celldex Therapeutics
American biopharmaceutical company
Nothing else this week.
Coverage
Newest first; wire copies grouped- Unknown outlet